Oppenheimer analyst Leland Gershell assigned a Buy rating to Ascendis Pharma (ASND) today and set a price target of $212.00. The company’s shares closed last Thursday at $137.82.
According to TipRanks.com, Gershell is a 4-star analyst with an average return of 11.0% and a 45.1% success rate. Gershell covers the Healthcare sector, focusing on stocks such as Milestone Pharmaceuticals, BioMarin Pharmaceutical, and Corbus Pharmaceuticals.
Currently, the analyst consensus on Ascendis Pharma is a Strong Buy with an average price target of $184.75, representing a 32.5% upside. In a report released yesterday, Canaccord Genuity also maintained a Buy rating on the stock with a $172.00 price target.
See today’s analyst top recommended stocks >>
Based on Ascendis Pharma’s latest earnings release for the quarter ending March 31, the company reported a quarterly revenue of $2.23 million and GAAP net loss of $63.32 million. In comparison, last year the company earned revenue of $5.41 million and had a GAAP net loss of $53.64 million.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Ascendis Pharma A/S is a biopharmaceutical company, which engages in the development of drug candidates. Through its TransCon technology, it develops a pipeline of sustained release prodrug therapies including endocrinology product candidates to support the market. The company was founded by Jan Moller Mikkelsen and Harald Rau in September 2006 and is headquartered in Hellerup, Denmark.
